
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is projected to see product sales rise significantly, from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust revenue growth potential. The company is optimizing its balance sheet through a $1.5 billion debt deal, which enhances financial flexibility amid uncertainties and allows for strategic opportunities. Improvements in manufacturing efficiency are expected to boost gross margins back to 50% in 2025, signaling a recovery from previous compressions and bolstering overall profitability as the firm's diverse mRNA pipeline advances.
Bears say
Moderna's stock outlook has turned negative primarily due to declining revenue from COVID-19 vaccine sales, which fell from $18 billion in 2022 to an anticipated $6.7 billion in 2023, with projections for further reductions in the coming years as vaccination rates decrease and the pandemic shifts toward an endemic phase. Additionally, the company's mRESVIA in respiratory syncytial virus (RSV) faces significant competition from already approved vaccines, limiting potential market share and revenue prospects. Given these factors, along with a slow pipeline progress outside of respiratory vaccines and anticipated low EU sales for 2024 and likely 2025, Moderna's long-term revenue growth potential appears substantially constrained, leading to a revised valuation of their COVID-related asset portfolio.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares